A new enhanced antibiotic treatment for early and late syphilis

Francesco Drago, Giulia Ciccarese, Francesco Broccolo, Giulia Sartoris, Paola Stura, Susanna Esposito, Alfredo Rebora, Aurora Parodi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The objective of this study was to evaluate the efficacy of an enhanced treatment regimen for syphilis with the addition of doxycycline and ceftriaxone to the conventional benzathine penicillin G (BPG) treatment. Sixty-nine syphilis patients were recruited and were randomly assigned to two groups: group 1 (38 patients) received standard therapy and group 2 (31 patients) received the enhanced therapy. All patients were followed-up for at least 12 months. Patients underwent physical examination and serology every 6 months as well as echocardiography and neurological examination every year. A three- to four-fold decline in the initial Venereal Disease Research Laboratory (VDRL) titre within 6 months after therapy was considered as serological cure. At 12 months, 68% of patients in group 1 and 100% in group 2 were serologically cured (P = 0.002). During follow-up, no patients in group 2 experienced complications related to syphilis. In contrast, one patient in group 1 developed neurosyphilis. In conclusion, the enhanced treatment is more effective than standard treatment and results in a higher and faster cure rate. Moreover, it provides treponemicidal antibiotic levels in the cerebrospinal fluid, thereby preventing possible late complications.

Original languageEnglish
Pages (from-to)64-66
Number of pages3
JournalJournal of Global Antimicrobial Resistance
Volume5
DOIs
Publication statusPublished - 2016

Fingerprint

Anti-Bacterial Agents
Syphilis
Therapeutics
Penicillin G Benzathine
Neurosyphilis
Ceftriaxone
Tertiary syphilis
Doxycycline
Neurologic Examination
Serology
Group Psychotherapy
Sexually Transmitted Diseases
Physical Examination
Cerebrospinal Fluid
Echocardiography
Research

Keywords

  • Benzathine penicillin G
  • Ceftriaxone
  • Doxycycline
  • Syphilis

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

A new enhanced antibiotic treatment for early and late syphilis. / Drago, Francesco; Ciccarese, Giulia; Broccolo, Francesco; Sartoris, Giulia; Stura, Paola; Esposito, Susanna; Rebora, Alfredo; Parodi, Aurora.

In: Journal of Global Antimicrobial Resistance, Vol. 5, 2016, p. 64-66.

Research output: Contribution to journalArticle

Drago, F, Ciccarese, G, Broccolo, F, Sartoris, G, Stura, P, Esposito, S, Rebora, A & Parodi, A 2016, 'A new enhanced antibiotic treatment for early and late syphilis', Journal of Global Antimicrobial Resistance, vol. 5, pp. 64-66. https://doi.org/10.1016/j.jgar.2015.12.006
Drago, Francesco ; Ciccarese, Giulia ; Broccolo, Francesco ; Sartoris, Giulia ; Stura, Paola ; Esposito, Susanna ; Rebora, Alfredo ; Parodi, Aurora. / A new enhanced antibiotic treatment for early and late syphilis. In: Journal of Global Antimicrobial Resistance. 2016 ; Vol. 5. pp. 64-66.
@article{23a2c349d1d24df1aef4295fbf75cb18,
title = "A new enhanced antibiotic treatment for early and late syphilis",
abstract = "The objective of this study was to evaluate the efficacy of an enhanced treatment regimen for syphilis with the addition of doxycycline and ceftriaxone to the conventional benzathine penicillin G (BPG) treatment. Sixty-nine syphilis patients were recruited and were randomly assigned to two groups: group 1 (38 patients) received standard therapy and group 2 (31 patients) received the enhanced therapy. All patients were followed-up for at least 12 months. Patients underwent physical examination and serology every 6 months as well as echocardiography and neurological examination every year. A three- to four-fold decline in the initial Venereal Disease Research Laboratory (VDRL) titre within 6 months after therapy was considered as serological cure. At 12 months, 68{\%} of patients in group 1 and 100{\%} in group 2 were serologically cured (P = 0.002). During follow-up, no patients in group 2 experienced complications related to syphilis. In contrast, one patient in group 1 developed neurosyphilis. In conclusion, the enhanced treatment is more effective than standard treatment and results in a higher and faster cure rate. Moreover, it provides treponemicidal antibiotic levels in the cerebrospinal fluid, thereby preventing possible late complications.",
keywords = "Benzathine penicillin G, Ceftriaxone, Doxycycline, Syphilis",
author = "Francesco Drago and Giulia Ciccarese and Francesco Broccolo and Giulia Sartoris and Paola Stura and Susanna Esposito and Alfredo Rebora and Aurora Parodi",
year = "2016",
doi = "10.1016/j.jgar.2015.12.006",
language = "English",
volume = "5",
pages = "64--66",
journal = "Journal of Global Antimicrobial Resistance",
issn = "2213-7165",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A new enhanced antibiotic treatment for early and late syphilis

AU - Drago, Francesco

AU - Ciccarese, Giulia

AU - Broccolo, Francesco

AU - Sartoris, Giulia

AU - Stura, Paola

AU - Esposito, Susanna

AU - Rebora, Alfredo

AU - Parodi, Aurora

PY - 2016

Y1 - 2016

N2 - The objective of this study was to evaluate the efficacy of an enhanced treatment regimen for syphilis with the addition of doxycycline and ceftriaxone to the conventional benzathine penicillin G (BPG) treatment. Sixty-nine syphilis patients were recruited and were randomly assigned to two groups: group 1 (38 patients) received standard therapy and group 2 (31 patients) received the enhanced therapy. All patients were followed-up for at least 12 months. Patients underwent physical examination and serology every 6 months as well as echocardiography and neurological examination every year. A three- to four-fold decline in the initial Venereal Disease Research Laboratory (VDRL) titre within 6 months after therapy was considered as serological cure. At 12 months, 68% of patients in group 1 and 100% in group 2 were serologically cured (P = 0.002). During follow-up, no patients in group 2 experienced complications related to syphilis. In contrast, one patient in group 1 developed neurosyphilis. In conclusion, the enhanced treatment is more effective than standard treatment and results in a higher and faster cure rate. Moreover, it provides treponemicidal antibiotic levels in the cerebrospinal fluid, thereby preventing possible late complications.

AB - The objective of this study was to evaluate the efficacy of an enhanced treatment regimen for syphilis with the addition of doxycycline and ceftriaxone to the conventional benzathine penicillin G (BPG) treatment. Sixty-nine syphilis patients were recruited and were randomly assigned to two groups: group 1 (38 patients) received standard therapy and group 2 (31 patients) received the enhanced therapy. All patients were followed-up for at least 12 months. Patients underwent physical examination and serology every 6 months as well as echocardiography and neurological examination every year. A three- to four-fold decline in the initial Venereal Disease Research Laboratory (VDRL) titre within 6 months after therapy was considered as serological cure. At 12 months, 68% of patients in group 1 and 100% in group 2 were serologically cured (P = 0.002). During follow-up, no patients in group 2 experienced complications related to syphilis. In contrast, one patient in group 1 developed neurosyphilis. In conclusion, the enhanced treatment is more effective than standard treatment and results in a higher and faster cure rate. Moreover, it provides treponemicidal antibiotic levels in the cerebrospinal fluid, thereby preventing possible late complications.

KW - Benzathine penicillin G

KW - Ceftriaxone

KW - Doxycycline

KW - Syphilis

UR - http://www.scopus.com/inward/record.url?scp=84955557383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955557383&partnerID=8YFLogxK

U2 - 10.1016/j.jgar.2015.12.006

DO - 10.1016/j.jgar.2015.12.006

M3 - Article

VL - 5

SP - 64

EP - 66

JO - Journal of Global Antimicrobial Resistance

JF - Journal of Global Antimicrobial Resistance

SN - 2213-7165

ER -